The role of PET/CT in preoperative decision-making for secondary cytoreduction in recurrent ovarian cancer

Secondary cytoreductive surgery is a feasible treatment option in recurrent ovarian cancer. Patient selection for surgery remains challenging, as conventional imaging, such as CT and MRI, is unreliable for predicting complete gross resection. PET/CT is a modality that combines metabolic and anatomical imaging. Although there are studies supporting the use of PET/CT in ovarian cancer, there is very limited evidence specifically assessing PET/CT-guided selection for secondary cytoreductive surgery under the latest eligibility criteria. This study aims to evaluate the added value of PET/CT for predicting no residual tumor volume after secondary surgical cytoreduction. We conducted a retrospective data collection on patients diagnosed with ovarian cancer who underwent a PET/CT examination between 2018 and 2023 in our center. Patients with suspected recurrence considered for secondary cytoreduction based on conventional imaging and clinical criteria, were included in our analysis. Besides descriptive statistics we performed decision curve analysis (DCA) to determine the added value of PET/CT in surgical decision-making. 22 patients were potentially eligible for secondary debulking according to clinical criteria and conventional imaging findings. 13/22 patients were found to be operable based on preoperative PET/CT results, and 11/13 had a successful resection (no gross residual tumor) (PPV: 85%). 9/22 patients were found ineligible for secondary cytoreduction based on PET/CT results. 7/9 had inoperable lesions, and in two cases, no malignant lesions were detected. Decision curve analysis showed that PET/CT provided superior clinical utility compared to both conventional imaging and a “treat none” approach, yielding a higher net benefit across a broad range of surgical decision thresholds. Our results demonstrate that PET/CT adds significant clinical value in selecting appropriate candidates for secondary cytoreduction, mainly by reinforcing potential operability. These findings suggest that PET/CT may provide incremental information during preoperative assessment; however, prospective validation is required.

Authors

Institutions

Publication Details

Journal
BMC Cancer
Published
2026-03-26
DOI
https://doi.org/10.1186/s12885-026-15898-3
Primary Topic
Ovarian cancer diagnosis and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The role of PET/CT in preoperative decision-making for secondary cytoreduction in recurrent ovarian cancer

Zoárd Tibor Krasznai, Csaba Csikos, Antal Varga, Ferenc Bátyi et al.
BMC Cancer
Ovarian cancer diagnosis and treatment
article

The role of PET/CT in preoperative decision-making for secondary cytoreduction in recurrent ovarian cancer

Zoárd Tibor Krasznai, Csaba Csikos, Antal Varga, Ferenc Bátyi, Zsolt Hascsi, Szabolcs Molnár, Ildikó Garai
article en

Abstract

Secondary cytoreductive surgery is a feasible treatment option in recurrent ovarian cancer. Patient selection for surgery remains challenging, as conventional imaging, such as CT and MRI, is unreliable for predicting complete gross resection. PET/CT is a modality that combines metabolic and anatomical imaging. Although there are studies supporting the use of PET/CT in ovarian cancer, there is very limited evidence specifically assessing PET/CT-guided selection for secondary cytoreductive surgery under the latest eligibility criteria. This study aims to evaluate the added value of PET/CT for predicting no residual tumor volume after secondary surgical cytoreduction. We conducted a retrospective data collection on patients diagnosed with ovarian cancer who underwent a PET/CT examination between 2018 and 2023 in our center. Patients with suspected recurrence considered for secondary cytoreduction based on conventional imaging and clinical criteria, were included in our analysis. Besides descriptive statistics we performed decision curve analysis (DCA) to determine the added value of PET/CT in surgical decision-making. 22 patients were potentially eligible for secondary debulking according to clinical criteria and conventional imaging findings. 13/22 patients were found to be operable based on preoperative PET/CT results, and 11/13 had a successful resection (no gross residual tumor) (PPV: 85%). 9/22 patients were found ineligible for secondary cytoreduction based on PET/CT results. 7/9 had inoperable lesions, and in two cases, no malignant lesions were detected. Decision curve analysis showed that PET/CT provided superior clinical utility compared to both conventional imaging and a “treat none” approach, yielding a higher net benefit across a broad range of surgical decision thresholds. Our results demonstrate that PET/CT adds significant clinical value in selecting appropriate candidates for secondary cytoreduction, mainly by reinforcing potential operability. These findings suggest that PET/CT may provide incremental information during preoperative assessment; however, prospective validation is required.

BMC Cancer
University of Debrecen (HU)
Peace, Justice and strong institutions
Openalex Percentile: Top 5%
Ovarian cancer diagnosis and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.